Synthesis, Anthelmintic and Anti-inflammatory Activities of Some Novel Imidazothiazole Sulfides and Sulfones

Nitinkumar S. Shetty,† Imtiyaz Ahmed M. Khazi,† and Chuljin Ahn

Department of Chemistry, Changwon National University, Changwon 641-773, Korea. †E-mail: snitinshetty@gmail.com

Department of Chemistry, Karnatak University, Dharwad-580 003, India

Received March 2, 2010, Accepted June 30, 2010

A series of new 6-aryl-3-(3,4-dimethoxy-phenyl)-2-phenylsulfanyl-imidazo[2,1-b]-thiazole (5a-c) and 6-aryl-2-benzensulfonyl-3-(3,4-dimethoxy-phenyl)imidazo[2,1-b]-thiazole (6a-c) have been prepared and characterized by analytical and spectral methods. The title compounds 5a-c and 6a-c were obtained by the reaction of 4-(3,4-dimethoxy-phenyl)-5-phenylsulfanyl-thiazol-2-ylamine (3) and 5-benzenesulfonyl-4-(3,4-dimethoxy-phenyl)thiazol-2-ylamine (4) with various phenacyl bromides in anhydrous ethanol. These newly synthesized compounds (5a-c and 6a-c) were screened for their anthelmintic and anti-inflammatory activities, where they have displayed better activities.

Key Words: Imidazo[2,1-b]thiazole, Sulfides, Sulfones, Anthelmintic activity, Anti-inflammatory activity

Introduction

A lot of work on the synthesis and biological activities of the condensed imidazo[2,1-b]-thiazoles has been reported since the discovery of novel broad spectrum anthelmintic, tetramisole.1 It is interesting to note that not a single drug better than tetramisole has been evaluated till now among the derivatives of imidazo[2,1-b]thiazoles. Imidazothiazole derivatives have been shown to display potent antitumor and fungistatic activities.2-4 In continuation of our work on nitrogen containing bridgehead heterocycles,5-7 herein we report synthesis of sulfides and sulfones of thiazolimidazoles expecting them to exhibit better anthelmintic and anti-inflammatory properties.

Results and Discussion

The synthetic pathway for the preparation of the title compounds is depicted in Scheme 1. 5-Bromo-4-(3,4-dimethoxy-phenyl)thiazol-2-ylamine (2) was obtained by the bromination of 4-(3,4-dimethoxy-phenyl) thiazol-2-ylamine (1).8 Nucleophilic displacement reaction of 5-bromo-4-(3,4-dimethoxy-phenyl)thiazol-2-ylamine (2) with an appropriate thiophenoxide anion resulted in the formation of 4-(3,4-dimethoxy-phenyl)-5-phenylsulfanyl-thiazol-2-ylamine (3). Oxidation of the sulfide (3) with hydrogen peroxide gave the respective sulfone (4). The imidazothiazole ring was synthesized by adopting the 3 + 2 approach wherein the nucleo-

Scheme 1
Table 1. Anthelmintic activities

<table>
<thead>
<tr>
<th>Compd. No.</th>
<th>Concentration % (w/v)</th>
<th>Paralysis time in minutes</th>
<th>Death time in minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>5a</td>
<td>2.5</td>
<td>42</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>1.0</td>
<td>38</td>
<td>80</td>
</tr>
<tr>
<td>5b</td>
<td>2.5</td>
<td>57</td>
<td>83</td>
</tr>
<tr>
<td></td>
<td>1.0</td>
<td>42</td>
<td>95</td>
</tr>
<tr>
<td>5c</td>
<td>2.5</td>
<td>74</td>
<td>150</td>
</tr>
<tr>
<td></td>
<td>1.0</td>
<td>89</td>
<td>175</td>
</tr>
<tr>
<td>6a</td>
<td>2.5</td>
<td>38</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>1.0</td>
<td>26</td>
<td>65</td>
</tr>
<tr>
<td>6b</td>
<td>2.5</td>
<td>44</td>
<td>119</td>
</tr>
<tr>
<td></td>
<td>1.0</td>
<td>52</td>
<td>127</td>
</tr>
<tr>
<td>6c</td>
<td>2.5</td>
<td>40</td>
<td>66</td>
</tr>
<tr>
<td></td>
<td>1.0</td>
<td>30</td>
<td>78</td>
</tr>
<tr>
<td>1% gum acacia (control)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Piperazine Citrate</td>
<td>1.0</td>
<td>21</td>
<td>72</td>
</tr>
</tbody>
</table>

Table 2. Anti-inflammatory activities

<table>
<thead>
<tr>
<th>Compd. No.</th>
<th>% Inhibition of edema</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral (po) 2 h</td>
<td>Oral (po) 3 h</td>
</tr>
<tr>
<td>5a</td>
<td>25</td>
</tr>
<tr>
<td>5b</td>
<td>13</td>
</tr>
<tr>
<td>5c</td>
<td>30</td>
</tr>
<tr>
<td>6a</td>
<td>40</td>
</tr>
<tr>
<td>6b</td>
<td>35</td>
</tr>
<tr>
<td>6c</td>
<td>32</td>
</tr>
<tr>
<td>Phenylbutazone</td>
<td>60</td>
</tr>
</tbody>
</table>

citrate, as a standard following the method described by Kakrani and Kalyani. A suspension of 2.5% (w/v) and 1% (w/v) of test compounds were prepared in 1% (w/v) of gum acacia. A standard solution of 1.0% (w/v) of piperazine citrate was prepared in 1% (w/v) gum acacia. Six worms of approximately same size were placed in each petridish containing 50 mL of the suspension of the test compounds and standard drug at the above mentioned concentration. The control test having six worms in 50 mL of 1% (w/v) of gum-acacia solution was also carried out simultaneously. The average time required for the paralysis and death of worms was recorded. The paralysis time of worms was the time when the worms show no movement after the drug administration but become active on transferring them into a beaker containing hot water at 40 °C. The death of worms was ascertained by the absence of movements of the worms in hot water. The results are given in Table 1.

Anti-inflammatory activity.

Materials and methods: The anti-inflammatory activity was studied as per the method described by Winter et al. The albino-rats (100 - 150 g) were divided into 10 groups each consisting of six animals. First group received solvent control (0.5 mL, 1% CMC) orally, next eight groups received the test compounds (200 mg/kg b.w) and the last group received phenylbutazone (150 mg/kg b.w). Inflammation was induced after 30 minutes of drug administration by injecting carregenin (0.05 mL of 1% solution) into the sub-planter tissue of the left hind paw in each rat. Then the volume of hind paw was measured by platsigraph at 0 hr and 3 hr. The percentage reduction of edema was calculated as follows:

\[ \% \text{ inhibition} = 100 \left( 1 - \frac{V_t}{V_c} \right) \]

Where \( V_t \) = Increase in volume of paw edema of treated animals. \( V_c \) = Increase in paw edema of control. The results are presented in Table 2.

Experimental Section

5-Bromo-4-(3,4-dimethoxy-phenyl)thiazol-2-ylamine (2).
To an ice cold solution of 4-(3,4-dimethoxy-phenyl)thiazol-2-ylamine (1) (0.1 mole) in glacial acetic acid (30 mL), a solution of bromine (5 mL, 0.1 mole) in acetic acid (10 mL) was added at 5 - 10 °C drop by drop during 30 minutes. It was further stirred at room temperature for 2 hrs and cooled in an ice bath.
The solid that separated was collected by filtration, washed with ice cold acetic acid (2 mL) and dried. It was then suspended in ice cold water and basified by ammonia solution to obtain free base. The acidic filtrate was cooled and basified when a small quantity of the base was obtained. It was combined with the main product and purified by recrystallisation from aqueous ethanol, pale yellow needles, Yield 70%, mp 128 - 130 °C; IR (KBr) vcm⁻¹ 3376, 3234, 2909; ¹H NMR (300 MHz, CDCl₃) δ 3.94 (s, 6H, OCH₃), 5.21 (s, 2H, NH), exchangeable with D₂O) 6.90 (d, 1H, J = 8.3, ArH), 7.41-7.47 (m, 2H, ArH). Anal. calcd. for C₁₁H₁₁BrN₂O₂S: C, 41.92; H, 3.52; N, 8.89. Found: C, 41.99; H, 3.42; N, 8.98%.

4-(3,4-Dimethoxy-phenyl)-5-phenylsulfanyl-thiazol-2-y1 amine (3). Thiophenol (11.0 g, 0.1 mole) in ethanol was added to a solution of sodium ethoxide (prepared from ethanol and metallic sodium) (2.3 g, 0.1 mole) with stirring at room temperature during 30 minutes. A solution of 5-bromo-4-(3,4-dimethoxy-phenyl)thiazol-2-ylamine (2) (0.1 mole) in ethanol was then added to this reaction mixture and it was refluxed for 5 hrs. The solvent was removed and the residue added to crushed ice (200 g). A solid that separated was collected by filtration and purified by crystallization from ethanol followed by column chromatography over neutral alumina using a mixture of benzene and chloroform (90:10 v/v) as eluent. Evaporation of the six first fractions gave a pure product, which showed a single spot on TLC plate. Yield 65%, mp 150 - 152 °C; IR (KBr) vcm⁻¹ 3367, 3249, 1628, 1530; ¹H NMR (300 MHz, CDCl₃) δ 6.90 (s, 6H, OCH₃), 4.84 (s, 2H, NH, exchangeable with D₂O), 6.86-7.52 (m, 8H, ArH). Anal. calcd. for C₁₇H₁₄BrN₂O₂S: C, 59.28; H, 4.68; N, 8.13. Found: C, 59.36; H, 4.50; N, 8.23%.

5-Benzenesulfonyl-4-(3,4-dimethoxy-phenyl)thiazol-2-y1 amine (4). To a solution of 4-(3,4-dimethoxy-phenyl)-5-phenylsulfanyl-thiazol-2-ylamine (3) (0.1 mole) in a minimum quantity of glacial acetic acid, was added hydrogen peroxide (6 mL, 30%) and the mixture stirred at room temperature for 48 hrs with the intermittent addition of hydrogen peroxide (1 mL) at every 12 hrs. A solid that separated was collected by filtration and purified by crystallization from alcohol. Yield 60%, mp 172 - 174 °C; IR (KBr) vcm⁻¹ 3373, 3228, 1322, 1139; ¹H NMR (300 MHz, CDCl₃) δ 3.90 (s, 6H, OCH₃), 5.02 (s, 2H, NH, exchangeable with D₂O), 6.50-7.52 (m, 8H, ArH). Anal. calcd. for C₁₇H₁₄BrN₂O₂S: C, 54.24; H, 4.28; N, 7.44. Found: C, 54.35; H, 4.20; N, 7.49%.

6-(p-Bromo-phenyl)-3-(3,4-dimethoxy-phenyl)-2-phenyl-sulfanyl-imidazo[2,1-b]-thiazole (5a). A mixture of 4-(3,4-dimethoxy-phenyl)-5-phenylsulfanyl-thiazol-2-ylamine (3) (0.01 mole) and phenacyl bromide (0.01 mole) in anhydrous ethanol (60 mL) was heated to reflux on a steam bath for 12 hrs. Excess of solvent was distilled off and the residue poured into ice cold water (200 mL) to get crude 6-(p-bromo-phenyl)-3-(3,4-dimethoxy-phenyl)-2-phenyl-sulfanyl-imidazo[2,1-b] thiazolium bromide. Neutralisation of above hydrobromide with aqueous sodium carbonate solution afforded the corresponding free base, 6-(p-bromo-phenyl)-3-(3,4-dimethoxy-phenyl)-2-phenyl-sulfanyl-imidazo[2,1-b]thiazole (5a). They were purified by column chromatography over neutral alumina using benzene-chloroform mixture (95%: 5% v/v) as eluent. Yield 45%, mp 189 - 191 °C; IR (KBr) vcm⁻¹ 1540, 1523, 1136; ¹H NMR (300 MHz, CDCl₃) δ 3.88 (s, 6H, OCH₃), 7.23-7.29 (m, 8H, ArH), 7.32 (d, J = 7.8 Hz, 2H, ArH), 7.51 (d, J = 8.0 Hz, 2H, ArH), 8.04 (s, 1H, C-5). Anal. calcd. for C₂₄H₁₇BrN₂O₂S: C, 57.36; H, 3.66; N, 5.35. Found: C, 57.44; H, 3.54; N, 5.49%.

Acknowledgments. This work was supported by Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0094066).

References
5. Andreani, A.; Rambaldi, M.; Leoni, A.; Morigi, M.; Locatelli, A.;